| |
| |
|
| Insider
Information: |
Smith Sandford D |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
386,982 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$925,106 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
386,982 |
|
|
| Total
Value |
$925,106 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
7
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -24.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ariad Pharmaceuticals Inc |
ARIA |
Director |
2007-06-20 |
131,205 |
2004-01-15 |
0 |
Premium* |
|
|
Genzyme Corp |
GENZ |
Exe VP,President Intl ... |
2011-04-04 |
0 |
2005-07-29 |
0 |
Premium* |
|
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
Director |
2016-11-29 |
0 |
2013-08-09 |
0 |
Premium* |
|
|
Palisade Bio Inc |
PALI |
Director |
2019-07-01 |
219,916 |
|
0 |
Premium* |
|
|
Seelos Therapeutics Inc |
SEEL |
Director |
2017-01-05 |
16,160 |
2014-10-22 |
0 |
Premium* |
|
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-01-27 |
900 |
2016-11-29 |
0 |
Premium* |
|
|
Cytokinetics Inc |
CYTK |
Director |
2024-01-02 |
18,801 |
2020-06-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PALI |
Palisade Bio Inc |
Director |
– • – |
2019-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
166,667 |
219,916 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
– • – |
2007-06-20 |
4 |
OE |
$1.50 |
$123,700 |
D/D |
45,000 |
131,205 |
0 |
- |
|
| PALI |
Palisade Bio Inc |
Director |
– • – |
2015-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
106,952 |
106,952 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
officerTitle |
– • – |
2005-12-01 |
4 |
OE |
$3.63 |
$36,300 |
D/D |
10,000 |
86,205 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
– • – |
2005-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
76,205 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
– • – |
2004-11-29 |
4 |
OE |
$2.00 |
$20,000 |
D/D |
10,000 |
66,205 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
Director |
– • – |
2004-01-16 |
4 |
OE |
$2.00 |
$35,714 |
D/D |
17,857 |
56,205 |
|
- |
|
| GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
• – – |
2010-07-23 |
4 |
OE |
$41.50 |
$1,427,082 |
D/D |
32,041 |
52,712 |
0 |
- |
|
| PALI |
Palisade Bio Inc |
Director |
– • – |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
45,046 |
50,899 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-09-30 |
4 |
A |
$0.34 |
$3,250 |
D/D |
9,607 |
49,093 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-06-30 |
4 |
A |
$0.40 |
$3,250 |
D/D |
8,136 |
39,486 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
• – – |
2011-04-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,500 |
35,171 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$2,813 |
D/D |
4,850 |
31,350 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Executive Vice President |
• – – |
2007-10-15 |
4 |
OE |
$46.24 |
$1,156,000 |
D/D |
25,000 |
30,112 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Executive Vice President |
• – – |
2007-10-10 |
4 |
OE |
$43.90 |
$1,105,222 |
D/D |
25,000 |
29,886 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
• – – |
2010-05-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
29,558 |
0 |
- |
|
| SEEL |
Seelos Therapeutics Inc |
Director |
– • – |
2014-10-23 |
4 |
B |
$1.59 |
$28,998 |
D/D |
18,200 |
26,500 |
2.39 |
- |
|
| GENZ |
Genzyme Corp |
Executive Vice President |
• – – |
2008-01-16 |
4 |
OE |
$46.24 |
$1,058,248 |
D/D |
20,181 |
25,486 |
0 |
- |
|
| PALI |
Palisade Bio Inc |
Director |
– • – |
2014-05-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2022-09-02 |
4 |
OE |
$10.68 |
$269,022 |
D/D |
11,369 |
23,539 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
• – – |
2010-05-25 |
4 |
S |
$45.60 |
$405,292 |
D/D |
(8,887) |
20,671 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
• – – |
2010-07-23 |
4 |
AS |
$63.75 |
$2,063,764 |
D/D |
(32,041) |
20,671 |
0 |
- |
|
| GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
• – – |
2011-04-04 |
4 |
D |
$74.00 |
$1,073,000 |
D/D |
(14,500) |
20,671 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2024-01-02 |
4 |
A |
$84.12 |
$12,450 |
D/D |
148 |
18,801 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
Director |
• • – |
2023-10-02 |
4 |
A |
$27.88 |
$12,490 |
D/D |
448 |
18,653 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
